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SI Methods 
Microarray analysis.  Tetrasaccharide and polysaccharide microarrays were prepared as 
described previously (1, 2).  Microarray experiments with the individual NTs were 
performed using methods described previously (3).  To measure glycosaminoglycan-
protein-protein interactions using the tetrasaccharide microarrays, a perimeter was drawn 
around 3 microarrays with a hydrophobic marker (PapPen) for each protein-receptor pair.  
The microarrays were treated with NaBH4 (5 min, 66 mM in PBS) and washed five times 
with PBS.  The first microarray was incubated with the protein ligand of interest (TNF-α, 
NGF, BDNF, NT-3, or NT-4/5; R&D Systems, 1 µM in 0.1% Triton X-100 in PBS).  The 
second microarray was incubated with the receptor of interest (TNFR1-Fc, TrkA-Fc, 
TrkB-Fc, TrkC-Fc, or TrkB-Fc, respectively; R&D Systems, 1 µM in 0.1% Triton X-100 
in PBS).  The third microarray was incubated with a 1:1 mixture of both the protein 
ligand and receptor (1 µM each in 0.1% Triton X-100 in PBS).  After 3 h, the 
microarrays were washed (5 × PBS) and treated with a rabbit primary antibody against 
the protein ligand (R&D Systems, 1:1000 in 0.1% Triton X-100 in PBS).  After 1 h, the 
microarray was washed (5 × PBS) and incubated with Cy3-conjugated anti-human Fc 
IgG and Cy5-conjugated anti-rabbit IgG antibodies (Invitrogen, 1:5000 in 0.1% Triton X-
100 in PBS) for 1 h.  The microarrays were then washed (3 × PBS, 2 × H2O) and dried 
under a stream of air.  A similar procedure was employed for the polysaccharide 
microarrays. After drawing perimeters around the array regions, the microarrays were 
incubated in 10% fetal bovine serum (FBS) in PBS for 1 h at 37 ºC.  The remainder of the 
procedure was identical, except that 1% FBS in PBS was used as the incubating buffer 
instead of 0.1% Triton X-100 in PBS.  All microarrays were analyzed using a GenePix 
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5000a scanner, and fluorescence quantification was performed using GenePix 6.1 
software with correction for local background.  Each protein was analyzed in triplicate, 
and the data represent an average of 8–10 spots for a given carbohydrate concentration.  
As controls, the microarrays were treated with the protein ligand (NT, TNFα or FGF2), 
followed by the anti-ligand antibody and Cy3 anti-human Fc IgG.  Similarly, the 
microarrays were incubated with the receptor (Trk-Fc, TNFR1-Fc or FGFR1-Fc), 
followed by the corresponding anti-ligand antibody (rabbit species) and Cy5 anti-rabbit 
IgG.  In all cases, no signal was observed, confirming that the antibodies showed no 
cross-reactivity (Fig. S11).    
 
 
Computational Methods.  Structures and Homology Models.  For the computational 
studies, the protein coordinates were obtained from solution or crystal structures when 
available.  Homology models were generated for protein complexes where such data was 
absent.  In all cases, crystal structures of highly related protein complexes were available 
for construction of the homology models.  The following PDB files were used: DBL3x 
(3BQK), DBL6 (2WAU), FGF2 solution structure (1BLA), FGF2-heparin co-crystal 
structure (1BFB), FGFR1 (1FQ9, chain C), FGF2-FGFR1 quaternary complex (1FQ9, 
chains A, B, C, D), FGF2-FGFR1-heparin co-crystal structure (1FQ9), TNF-α trimer 
(1TNF), TNF-β-TNFR1 (1TNR), NT-4/5 dimer (1B98 and 1HCF, chains A, B), human 
NGF dimer (2IFG, chains E, F), mouse NGF dimer (1BET), NT-3 dimer (1NT3), BDNF 
monomer (1BND, chain A), TrkA ligand-binding domain (1WWW chain X), TrkB 
ligand-binding domain (1HCF, chain X), NGF-TrkA complex (1WWW). 
The TNF-α-TNFR1 homology model was determined by aligning chain B of 
TNF-α in the TNF-α trimer crystal structure with TNF-β in the TNF-β-TNFR1 crystal 
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structure (TNF-α, TNF-β RMSD = 1.08 Å) and replacing TNF-β with the TNF-α trimer 
structure.  The BDNF dimer homology model was constructed by replacing the NT-3 
monomer with the BDNF monomer in the BDNF-NT-3 dimer structure from the PDB 
file 1BND (BDNF, NT-3 RMSD = 0.967 Å).  The NT-4/5-TrkA homology model was 
created by replacing TrkB in the PDB file 1HCF with TrkA (TrkA, TrkB RMSD = 0.804 
Å).   The BDNF-TrkB homology model was created by replacing the NT-4/5 dimer in the 
PDB file 1HCF with the BDNF dimer homology model (NT-4/5 dimer, BDNF dimer 
RMSD = 0.757 Å).  The NT-3-TrkA homology model was created by replacing the NT-
4/5 dimer and TrkB in the PDB file 1HCF with the NT-3 dimer and TrkA, respectively 
(NT-4/5 dimer, NT-3 dimer RMSD = 1.042 Å).   
The DREIDING FF (4) was used throughout the modeling.  Protein files were 
downloaded from the RCSB Protein Data Bank (www.pdb.org) and loaded into the Swiss 
PDB Viewer (5) to fix incomplete side chains.  The WhatIF program (6) was used to add 
hydrogen atoms. CHARMM22 (7) charges were added, and the protein was fully 
minimized in the presence of sodium and chloride ions under conditions of Surface 
Generalized Born (SGB) continuum solvation (8).   
The structures of a heparin tetrasaccharide and octasaccharide were extracted 
from the PDB files 1BFB and 1FQ9, respectively (heparin ‘A’).  Hydrogen atoms were 
added and charges were assigned to each atom using the charge equilibration (QEq) 
method (9).  The ligands were then fully minimized under conditions of Surface 
Generalized Born (SGB) continuum solvation (8).  The solution structures of the CS-A, 
CS-C, and CS-E tetrasaccharides were determined using molecular dynamics as reported 
(3). 
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Putative Binding Site Determination.  Coarse binding sites were first determined by rigid 
body docking of one oligosaccharide conformation as described previously (10), except 
with the following modifications.  The parameters radmax = 5.0 and dotlim = –0.5 were 
used for the autoMS program in Dock4.0 when creating the molecular surface.  To 
determine the potential binding site, the twenty-five lowest energy docked structures and 
corresponding binding sites were tabulated and ranked by energy.  Next, the sum of the 
inverse energy ranks for each binding site was determined.  Any binding site with a value 
of 1 or greater was considered a potential glycosaminoglycan binding site. 
Final Binding Site Determination.  The potential glycosaminoglycan binding sites were 
inputted into GenMSCDock (11), and rigid body docking of one oligosaccaride 
conformation was performed with standard input parameters.  Briefly, up to 120 different 
docked orientations were obtained in the first step, which represented the 40 lowest 
energy orientations each, as measured by Coulombic interaction energy, van der Waals 
interaction energy, and total interaction energy.  Next, for each of these structures, 
residues within 4 Å of any of the bound oligosaccharides were rotated, the complexes 
were briefly minimized, and the energy was calculated.  Finally, the universal cavity 
energy, which consists of the energy of the oligosaccharide and those protein residues 
within 5 Å of the oligosaccharide, was determined.  Residues within 5 Å of the 
oligosaccharide in more than one of the five minimum energy structures were considered 
part of the glycosaminoglycan binding site.  The average binding energies of the CS-A, 
CS-C, and CS-E tetrasaccharides were determined by averaging the differences between 
the energy of the docked CS-protein structure and the combined energy of the individual 
CS and protein structures for the five minimum energy structures.   
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Images were created using PyMOL (12), and the electrostatic maps were derived 
using Adaptive Poisson-Boltzmann Solver (APBS) software (13). 
 
Cellular Assays.  PC12 cells were propagated on collagen-coated 10-cm dishes in 
DMEM (Gibco) supplemented with 6.5% FBS, 6.5% horse serum, 2 mM L-glutamine, 
100 U·ml-1 penicillin, and 100 U·ml-1 streptomycin. Cells were grown at 37 ºC in a 
humidified atmosphere enriched with 5% CO2 and sub-cultured at a 1:3 ratio every 5–6 
days.  For the assays, PC12 cells were cultured on poly-DL-lysine-coated 60-mm dishes 
and grown as described above.  After 4–5 days (70–80% confluence), the media was 
replaced with a minimal media composed of DMEM supplemented with 0.5% FBS, 1% 
horse serum, 2 mM L-glutamine, 100 U·ml–1 penicillin, and 100 U·ml–1 streptomycin.  
Cells were incubated for 12 h before use in the following experiments.  
For chondroitinase experiments, 1 U·ml–1 chondroitinase ABC (Seikagaku) was 
added to the media. After 2 h, the cells were gently washed with fresh media three times 
before treatment.  For experiments with adsorbed CS-E on the dish, cells were split 1:1 
and plated on poly-DL-lysine dishes that had been incubated with a solution of CS-E-
enriched polysaccharides (500 ng·ml–1in PBS; Seikagaku) for 12 h at 37 ºC and then 
washed (3 x PBS).  The cells were allowed to adhere to the dish for 2–3 h prior to 
treatment.  For experiments with exogenous CS-E in solution, cells were exposed to fresh 
media containing CS-E-enriched polysaccharides (500 ng·ml–1 or 5000 ng·ml–1) for 2 h 
prior to treatment.  In all cases, cells treated with NTs were exposed to NGF (5 ng·ml–1) 
for 5 min, NT-4/5 (0.5 µg·ml–1) for 15 min, or a vehicle control.  The cells were 
subsequently washed (3 × PBS), lysed, and analyzed as previously described (14). 
Western blots were analyzed by blotting for total TrkA (763; Santa Cruz Biotechnology) 
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and p-TrkA (Y490; Cell Signaling).  Relative TrkA activation was calculated by dividing 
p-TrkA signal by total TrkA signal for each condition and normalizing with respect to the 
control (NT treatment of WT cells). 
 
Immunohistochemistry.  PC12 cells were grown on poly-DL-lysine-coated coverslips 
and treated with chondroitinase as described above.  For the co-localization studies, cells 
were treated with NGF for 60 min.  Following each treatment, cells were fixed with 4% 
paraformaldehyde in PBS for 20 min, washed (2 × PBS), and permeabilized with 0.5% 
Triton-X 100 for 5 min.  After washing (2 × PBS), cells were blocked with 10% FBS in 
PBS for 1 h and then incubated with an anti-CS-E mouse antibody (3, 15) (1:500) and an 
anti-tubulin rat antibody (Sigma, 1:1000) in 10% FBS in PBS for 3 h.  The cells were 
washed (5 × PBS), treated with anti-mouse-AlexaFluor488 (Invitrogen, 1:1000) and anti-
rat-AlexaFluor546 (Invitrogen, 1:1000) secondary antibodies for 1 h, washed again (5 × 
PBS), mounted onto slides, and then imaged by confocal fluorescence microscopy.  
Images were analyzed using ImageJ (http://rsbweb.nih.gov/ij/) using the RG2B Co-
localization plugin, which returns a pixel in the blue channel for each pixel with signal 
from both the red and green channel.  The total number of pixels in the blue channel were 
counted for each cell and normalized with respect to area.  
 
ELISA.  TrkA (3.3 µg·ml–1 in 50 mM Na2CO3, pH 9.6; 25 µl per well) was added to a 
384-well plate (Maxisorp) and incubated in a humidified chamber at 4 ºC for 12 h.  The 
wells were blocked with 1% BSA in PBS at 25 °C for 2 h.  Varying concentrations of 
NGF, NT-3, or NT-4/5 (0.45 – 230 nM in 0.1% BSA in PBS) were added to each 
well.  After 2 h, the wells were incubated with a rabbit antibody against the NT of interest 
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(1:1000 in 0.1% BSA in PBS) at 25 °C for 1 h, followed by an anti-rabbit antibody 
conjugated to horseradish peroxidase (Invitrogen, 1:10,000 in 0.1% BSA in PBS) at 25 
°C for 1 h.  Between each incubation, the wells were washed three to five times in 0.05% 
Tween-20 in PBS.  NT binding was detected using a TMB Substrate Kit (Pierce) 
according to the manufacturer’s protocol. 
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Supporting Figure Legends 
 
 
Figure S1. Structures of representative glycosaminoglycan family members.  For 
heparin, heparan sulfate, dermatan sulfate, and keratan sulfate: R = H or SO3–, R’ = H, 
Ac, or SO3–. n = 10-200. 
 
Figure S2. Co-localization of FGF2 (red) and FGFR1 (green) on the polysaccharide 
microarray 
 
Figure S3. (A) Relative binding of TNF-α to the indicated tetrasaccharide of defined 
sulfation sequence in the presence (red) or absence (black) of TNFR1.  (B) Relative 
binding of TNFR1 to the indicated tetrasaccharide of defined sulfation sequence in the 
presence (red) or absence (black) of TNF-α.  Binding relative to the maximum signal for 
each plot is shown.  Each protein was analyzed in triplicate, and the data represent an 
average of 8–10 spots for a given carbohydrate concentration. 
 
Figure S4.  (A) Relative binding of TrkC to the indicated tetrasaccharides in the presence 
(red) or absence (black) of NT-3.  (B) Relative binding of TrkB to the indicated 
tetrasaccharides in the presence (red) or absence (black) of NT-4/5.  Binding relative to 
the maximum signal for each plot is shown.  Each protein was analyzed in triplicate, and 
the data represent an average of 8–10 spots for a given carbohydrate concentration. 
 
Figure S5. Binding of Trk receptors to the indicated polysaccharides at 0.5, 5, and 10 µM 
concentration in the presence (red) or absence (black) of the indicated NT. 
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Figure S6. Binding of the indicated NTs to immobilized TrkA, as determined by ELISA. 
NGF has the strongest affinity for TrkA. NT-3 and NT-4/5 also bind, but with >100-fold 
weaker affinity. 
 
Figure S7.  Comparison of predicted CS-E binding sites (yellow and green) on the 
BDNF, NGF, NT-4/5, and NT-3 dimer.  Residues highlighted in green correspond to 
monomer A of the dimer; residues highlighted in yellow correspond to monomer B.  NT-
3 does not contain β-strands 4 and 5. 
 
Figure S8. Predicted CS-E binding sites in the (A) BDNF, NGF, NT-4/5, and NT-3 
dimers and (B) the NT binding domain (domain 5) of TrkA and TrkB.  Top: Ribbon 
representation of each protein.  Middle: Connolly surface with CS-E binding sites 
depicted in blue (non-basic residues) and yellow (basic residues).  Bottom: Electrostatic 
maps generated by Adaptive Poisson-Boltzmann Solver software.  All images were 
created in PyMOL. 
 
Figure S9.  Predicted CS-E binding sites in the NGF-TrkA, BDNF-TrkB, NT-3-TrkA, 
and NT-4/5-TrkA complexes.  Top: Ribbon representation of each protein.  Middle: 
Connolly surface with CS-E binding sites depicted in blue (non-basic residues) and 
yellow (basic residues).  Bottom: Electrostatic maps generated by Adaptive Poisson-
Boltzmann Solver software.  All images were created in PyMOL. 
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Figure S10. Treatment of PC12 cells with ChABC results in loss of CS-E-positive 
immunostaining. 
 
Figure S11. Microarray controls to confirm lack of antibody cross-reactivity. (A) NGF 
binding to the microarray was detected using an anti-NGF rabbit primary antibody and 
anti-rabbit IgG secondary antibody conjugated to Cy5. (B) No signal was observed with 
the anti-Fc antibody conjugated to Cy3 used to detect Trk-Fc receptors. (C) TrkA-Fc 
binding to the microarray was detected using an anti-Fc antibody conjugated to Cy3. (D) 
No signal was observed with the anti-rabbit antibody conjugated to Cy5 used to detect 
NGF. 
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Table S1. Predicted CS-A binding site on the 
DBL6 domain of VAR2CSA and associated 
KD values for the interaction of DBL6 mutants 
with purified CS-A 
Predicted CS-A 
Binding Site 
KD values of DBL6 
mutantsa 
Lys2388  
Arg2389  
Asp2390  
Pro2391  
Lys2392 Lys2932Ala: NDb 
Phe2394  
Lys2395 Lys2395Ala: NDb 
Ile2452  
Leu2453  
Gly2454  
Lys2462  
Trp2466  
Met2469  
Asn2470  
a Data are from reference 28. For comparison, 
WT DBL6 had a KD value of 80 µM. Blank entries 
correspond to residues whose contribution to the 
binding site was not tested 
b  KD value too weak to be determined 
 
Table S2. Predicted CS-A binding site on the 
DBL3x domain of VAR2CSA and associated KD 
values for the interaction of DBL3x mutants with 
purified CS-A 
Predicted CS-A 
Binding Site 
KD values of DBL3x 
mutantsa 
Asp1236  
Gly1237  
Lys1238  
Ile1239  
Phe1240  
Gly1242  
Lys1243 Lys1243Ala: 367 µM 
Gly1244  
Gly1245  
Glu1246  
Gly1318  
Thr1319  
Ile1321  
Lys1324 Lys1324Ala: 122 µM 
Asn1325  
Lys1328 Lys1328Ala: 89 µM 
Gly1329  
Gln1330  
Arg1467 Arg1467Ala: 122 µM 
Arg1503  
 Lys1504Ala: 172 µM 
Lys1507  
Lys1510 Lys1510Ala: 193 µM 
 Lys1515Ala: 488 µMb 
a Data are from reference 28. For comparison, WT 
DBL3x had a KD value of 33 µM.  Blank entries 
correspond to residues whose contribution to the 
binding site was not tested 
b Corresponds to a buried lysine residue that may not 
directly interact with CS-A 
 
Table S3. Comparison of the heparin 
binding site on FGF2 as determined 
using computational and 
crystallographic methodsa 
Computational 
Prediction 
Crystal 
Structure 
Lys26b  
Asn27 Asn27 
Gly28  
Leu118 Leu118 
Lys119 Lys119 
Arg120 Arg120 
Thr121 Thr121 
Lys125 Lys125 
Lys129 Lys129 
Gly133 Gly133 
Gln134 Gln134 
Lys135 Lys135 
Ala136 Ala136 
 Ile137 
a Residues are numbered according to 
FGF2 structure 1FQ9 
b Found in the heparin binding site of the 
structure 1BFC 
 
Table S4. Comparison of the heparin binding site in the FGF2-FGFR1 complex 
determined using computational or crystallographic methods  
Computational 
Prediction 
Crystal 
Structurea  
Computational 
Prediction 
Crystal 
Structurea 
FGF2 A, Lys26 FGF2 A, Lys26  FGFR1 A, Lys160 FGFR1 A, Lys160 
FGF2 A, Asn27 FGF2 A, Asn27  FGFR1 A, Lys163 FGFR1 A, Lys163 
FGF2 A, Gly28 FGF2 A, Gly28  FGFR1 A, His166 FGFR1 A, His166 
FGF2 A, Leu118 FGF2 A, Leu118  FGFR1 A, Val168  
FGF2 A, Lys119 FGF2 A, Lys119  FGFR1 A, Lys172 FGFR1 A, Lys172 
FGF2 A, Arg120 FGF2 A, Arg120  FGFR1 A, Thr173 FGFR1 A, Thr173 
FGF2 A, Thr121 FGF2 A, Thr121  FGFR1 A, Val174 FGFR1 A, Val174 
FGF2 A, Lys125 FGF2 A, Lys125  FGFR1 A, Lys175 FGFR1 A, Lys175 
 FGF2 A, Leu126  FGFR1 A, Phe176  
 FGF2 A, Ser128  FGFR1 A, Lys177 FGFR1 A, Lys177 
FGF2 A, Lys129 FGF2 A, Lys129   FGFR1 A, Tyr206 
FGF2 A, Gly133 FGF2 A, Gly133  FGFR1 A, Lys207 FGFR1 A, Lys207 
FGF2 A, Gln134 FGF2 A, Gln134   FGFR1 A, Val208 
FGF2 A, Lys135 FGF2 A, Lys135  FGFR1 A, Arg209 FGFR1 A, Arg209 
FGF2 A, Ala136 FGF2 A, Ala136  FGFR1 A, Thr212  
 FGF2 A, Ile137  FGFR1 A, Ser214  
 FGF2 B, Tyr24  FGFR1 A, Ile216 FGFR1 A, Ile216 
FGF2 B, Lys26 FGF2 B, Lys26  FGFR1 A, Asp218 FGFR1 A, Asp218 
FGF2 B, Asn27 FGF2 B, Asn27  FGFR1 B, Lys160 FGFR1 B, Lys160 
FGF2 B, Gly28 FGF2 B, Gly28  FGFR1 B, Lys163 FGFR1 B, Lys163 
 FGF2 B, Gly29  FGFR1 B, His166 FGFR1 B, His166 
 FGF2 B, Ala117  FGFR1 B, Val168 FGFR1 B, Val168 
FGF2 B, Leu118 FGF2 B, Leu118  FGFR1 B, Lys172  
FGF2 B, Lys119 FGF2 B, Lys119  FGFR1 B, Thr173 FGFR1 B, Thr173 
FGF2 B, Arg120 FGF2 B, Arg120  FGFR1 B, Val174  
FGF2 B, Thr121   FGFR1 B, Lys175 FGFR1 B, Lys175 
FGF2 B, Lys125 FGF2 B, Lys125  FGFR1 B, Phe176  
 FGF2 B, Leu126  FGFR1 B, Lys177  
 FGF2 B, Ser128   FGFR1 B, Tyr206 
FGF2 B, Lys129 FGF2 B, Lys129  FGFR1 B, Lys207 FGFR1 B, Lys207 
 FGF2 B, Thr130   FGFR1 B, Val208 
 FGF2 B, Gly131  FGFR1 B, Arg209 FGFR1 B, Arg209 
FGF2 B, Gly133 FGF2 B, Gly133  FGFR1 B, Thr212  
FGF2 B, Gln134 FGF2 B, Gln134  FGFR1 B, Ser214  
FGF2 B, Lys135 FGF2 B, Lys135  FGFR1 B, Ile216 FGFR1 B, Ile216 
FGF2 B, Ala136 FGF2 B, Ala136  FGFR1 B, Asp218 FGFR1 B, Asp218 
 FGF2 B, Ile137    
a Residues found within 5 Å of heparin in the heparin-FGF2-FGFR1 structure 1FQ9 
 
Table S5. Predicted CS-E binding site  
on TNF-α 
Monomer A  Monomer B 
Ser71  Lys65 
Thr72  Gln67 
His73  Gly108 
Val74  Ala109 
Leu75  Glu110 
Arg103  Ala111 
Thr105  Lys112 
Arg138  Pro113 
  Tyr115 
  Leu143 
 
Table S6. Average binding energies (kcal/mol) of CS-A, CS-C, and CS-E for TNF-α 
and the NTs  
 TNF BDNF NGF NT-4/5 NT-3 
CS-A -116.80 ± 12.57 -560.93 ± 7.29 -265.65 ± 8.47 -250.11 ± 15.71 -309.20 ± 15.89 
CS-C -114.23 ± 11.29 -538.91 ± 20.16 -220.21 ± 10.45 -240.06 ± 10.30 -315.32 ± 11.42 
CS-E -176.12 ± 10.22 -824.94 ± 9.25 -446.0 ± 8.69 -407.77 ± 25.07 -569.74 ± 19.10 
 
Table S7. Predicted CS-E binding sites on the NTs and Trks 
BDNF NGF NT-4/5 NT-3 TrkA TrkB 
Monomer A, 
Met31 
Monomer A, 
Ile31 
Monomer A, 
Arg34 
Monomer A, 
Arg56 Ala310 Ala314 
Monomer A, 
Ser32 
Monomer A, 
Lys32 
Monomer A, 
Arg36 
Monomer A, 
Cys57 Pro311 Gln316 
Monomer A, 
Arg88 
Monomer A, 
Lys34 
Monomer A, 
Asp103 
Monomer A, 
Glu59 Ser312 Phe318 
Monomer A, 
Arg97 
Monomer A, 
Asp93 
Monomer A, 
Ala104 
Monomer A, 
Ala60 Leu313 Ala322 
Monomer A, 
Trp100 
Monomer A, 
Gly94 
Monomer A, 
Gln105 
Monomer A, 
Arg61 Arg314 Ile323 
Monomer A, 
Arg101 
Monomer A, 
Lys95 
Monomer A, 
Arg107 
Monomer A, 
Asn76 Leu316 Leu324 
Monomer A, 
Phe102 
Monomer A, 
Gln96 
Monomer A, 
Gly109 
Monomer A, 
Ser77 Gly319 Asn325 
Monomer B, 
Trp19 
Monomer A, 
Ala97 
Monomer A, 
Trp110 
Monomer A, 
Gln78 Val321 Ile362 
Monomer B, 
Thr21 
Monomer A, 
Ala98 
Monomer A, 
Arg111 
Monomer A, 
Cys79 Asn323 Lys364 
Monomer B, 
Lys41 
Monomer A, 
Trp99  
Monomer A, 
Lys80 Glu324 Lys369 
Monomer B, 
Val44 
Monomer A, 
Arg100  
Monomer A, 
Thr81 Thr330  
Monomer B, 
Lys46 
Monomer B, 
Asn46  
Monomer A, 
Gln83 Glu331  
Monomer B, 
Gly47 
Monomer B, 
Ser47  
Monomer A, 
Arg103 Phe332  
Monomer B, 
Gln48 
Monomer B, 
Val48  
Monomer A, 
Ala111 Arg342  
Monomer B, 
Leu49 
Monomer B, 
Phe49  
Monomer A, 
Leu112 Thr360  
Monomer B, 
Lys50 
Monomer B, 
Lys50  
Monomer A, 
Ser113 Leu362  
Monomer B, 
Tyr52 
Monomer B, 
Tyr52  
Monomer A, 
Arg114 Ala364  
Monomer B, 
Tyr54   
Monomer A, 
Lys115 Asn365  
   Monomer B, Arg8 Pro366  
   Monomer B, Glu10 Gly368  
   Monomer B, Tyr11 Gln369  
    Ser371  
 
